Nyrada (ASX:NYR) has confirmed growing clinical momentum, strengthening finances, and expanding scientific validation for its lead candidate, Xolatryp, as the company positions itself for its next phase of development. …
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 24 April
April 24, 2026 - - Podcast -
Prevention warning as Pfizer urges Budget reset on vaccines and immunisation
April 24, 2026 - -
NDIS fraud is so extensive that 'prosecuting our way out of it' is now impractical
April 24, 2026 - - Latest News -
Boehringer Ingelheim and Heart of Australia take mobile lung care deeper into regional Australia
April 24, 2026 - - Latest News -
A decade to diagnosis highlights hidden burden of immune disorders
April 24, 2026 - - Latest News -
Quiet diplomacy as Australia navigates global pricing pressure, but can it work?
April 24, 2026 - - Latest News -
New immunotherapy option approved for Australians with relapsed follicular lymphoma
April 24, 2026 - - Latest News